5 urologic oncology headlines you missed in Q2 2026

The second quarter of 2026 brought several practice-changing developments across genitourinary oncology, from new FDA approvals to pivotal phase 3 data presented at major scientific meetings. Advances in bladder, prostate, and kidney cancer expanded treatment options in both the adjuvant and perioperative settings while highlighting the growing role of biomarker-guided care and combination strategies.